
Mandelic Acid: Exfoliates skin; clinical evidence is mainly from professional acne peels. Tranexamic Acid: Topical formulas are studied for melasma, with mixed results.


Consider for exfoliation; evidence for acne comes mainly from supervised peels.
Consider a topical pigment option; the evidence is mixed and formula-specific.
Can you use both?
A gentle pairing for dark marks and melasma.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Loosens outer cells: An acidic formula helps reduce cell adhesion. Promotes shedding: Strength, pH and contact time affect the response.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Mandelic acid skincare and office peels are different products. Controlled acne studies have used professional peels around 40–45%; those strengths are not a target for facial home use.
40–45%
Studied professional peels
Clinician-applied peels studied for mild-to-moderate acne. This describes specific procedures, not a recommended home concentration.
Choosing a strength: For home skincare, use the finished product’s label and your tolerance. Do not assume that a marketed serum reproduces an office peel study.
Higher strengths: Mandelic acid can still burn or irritate skin. Being described as a gentler acid does not make concentrated peels suitable for unsupervised use.
Formula matters: Acidity, vehicle and exposure time influence the effect; percentage alone cannot rank safety or compare mandelic acid with other acids.
Topical tranexamic acid studies have used different delivery systems, including 1.8% liposomal lotion and 5% creams or solutions. Oral treatment and procedure-assisted delivery are separate medical decisions.
1.8%
5%
Studied liposomal lotion
One melasma trial tested this delivery system. Its percentage cannot be directly compared with an ordinary serum.
Studied topical formulas
Several melasma studies used topical formulas at this strength. Evidence does not establish one best concentration for all pigment concerns.
Choosing a strength: Look for evidence on the finished topical product. Do not use injectable or oral products as DIY skincare.
Higher strengths: A stronger topical percentage has not been shown to guarantee better results. Oral use requires separate evaluation of risks, including clotting risk.
Formula matters: Liposomal delivery, other brightening ingredients and procedures can change the treatment. A microneedling study is not evidence for the same result from a home serum.
Approximate windows, not promises.
First few weeksAssess tolerance and texture; immediate softness can come from the base formula.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksSubtle changes may appear in some tested products; evidence varies.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksCompare photographs in the same lighting and reassess benefit.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsPhotoaging trials often need several months; expect modest rather than dramatic change.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term evidence is limited for many cosmetic actives; continue only if useful.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Can cause stinging, peeling or irritation; avoid active eczema and rosacea flares.
Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Low-strength leave-on acids are generally considered acceptable; avoid peels and ask the clinician managing your pregnancy.
Melasma is common in pregnancy, so this comes up constantly. Oral tranexamic acid is not a casual pregnancy decision, and the topical version has little pregnancy-specific data. Ask the doctor managing your pregnancy, since they know your full picture.
On the skin. The finished product delivers mandelic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Promotes shedding of surface cells; formula acidity and contact time influence irritation and effect.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers tranexamic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. May affect plasmin-related signalling involved in pigmentation; a small molecular size does not guarantee delivery.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Consider for exfoliation; evidence for acne comes mainly from supervised peels.
A 50-person, 12-week trial compared 45% mandelic with 30% salicylic peels. It had no vehicle arm and does not establish the benefit of 5–10% home serums.
Consider a topical pigment option; the evidence is mixed and formula-specific.
A small vehicle-controlled 5% trial did not show superiority over vehicle. A larger active-comparator study found improvement in both groups but did not prove equivalence to hydroquinone.
Sources